Stock Ticker

  • Loading stock data...

Buzzing Stocks: Rubicon Technology Inc. (NASDAQ:RBCN), CombiMatrix Corp (NASDAQ:CBMX), Alcobra Ltd (NASDAQ:ADHD)

Boston, MA 10/08/2014 (wallstreetpr) – Shares of Rubicon Technology, Inc. (NASDAQ:RBCN) went up by 7.75% in yesterday’s trading session after the news of its biggest competitor GT Advanced Technologies Inc (NASDAQ:GTAT) has filed for Chapter 11 bankruptcy protection. Investors were betting that the Illinois firm is likely to gain more orders from the likes of Apple Inc. (NASDAQ:AAPL), while its competitor sorts out its financial mess. The company has announced that it has capability to produce sapphire glass in the shape of   “rectangular blocks ready to be sliced into smartphone face plates.” Incidentally, shares of GT Advanced Technologies Inc (NASDAQ:GTAT) were also much sought after among the investor community yesterday.

Molecular diagnostics solutions designer and manufacturer CombiMatrix Corp (NASDAQ:CBMX) announced on October 7 that it anticipates reporting that its proprietary “prenatal testing” has achieved record volumes during the 3Q operations. It has indicated that its preliminary data indicate a 71 percent increase in the number of prenatal tests conducted during the 3Q in comparison to 3Q13. The surge in volume is being linked to the firm’s shift in focus to concentrate on increasing its presence in the “prenatal molecular diagnostics testing markets.” CombiMatrix Corp (NASDAQ:CBMX) closed higher at $1.20 which was a surge of 10.09%.

Biopharmaceutical firm Alcobra Ltd (NASDAQ:ADHD) was upgraded by rating agencies FBR Capital and WBB Securities on 7th October. FBR Capital upgraded the stock to Outperform from previous recommendation of Market perform. WBB Securities has pushed its rating on the stock to Speculative Buy from previous Buy rating. The upgrades come on the back of the drug maker announcement on 6th October. It released positive “Topline Results from Phase III Study of MDX” to treat adults suffering from attention deficit disorder. The shares of the drug maker were up by 6.37% to close at $6.51.

Published by Lisa Ray

Lisa has a Bachelor of Arts in journalism from Purdue University and 3 years of experience in the publishing field.



  • Recent Stories

    SignUp Now For Our Featured Newsletter

    Sign Up To Get Our Latest Stocks Alerts